检索结果-南通市图书馆

Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients:Results of a multicenter,double-blind,double-dummy,clinical trial at 96 weeks

引用

World Journal of Clinical Cases 2021年第18期9卷 4690-4699页

作者： xiao-Fan Chen Ya-Nan Fan Chong-Wen Si Yan-Yan Yu Jia Shang Zu-jiang Yu Qing Mao Qing Xie Wei Zhao Jun li Zhi-liang Gao Shan-ming wu Hong tang Jun Cheng Xin-Yue Chen Wen-Hong zhang hao Wang Zhong-Nan Xu ling Wang Jun dai Jing-Hang Xu Department of Infectious Diseases Center for Liver DiseasesPeking University First HospitalBeijing 100034China Department of Infectious Diseases Henan Provincial People's HospitalZhengzhou 450003Henan ProvinceChina Department of Infectious Diseases The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052Henan ProvinceChina Department of Infectious Diseases Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China Department of Infectious Diseases Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025China Department of Infectious Diseases The Second Affiliated Hospital of Southeast UniversityNanjing 210011Jiangsu ProvinceChina Department of Infectious Diseases The First Affiliated Hospital with Nanjing Medical UniversityNanjing 210029Jiangsu ProvinceChina Department of Infectious Diseases The Third Affiliated HospitalSun Yat-sen UniversityGuangzhou 510630Guangdong ProvinceChina Department of Infectious Diseases Shanghai Public Health Clinical CenterFudan UniversityShanghai 201052China Department of Infectious Diseases West China Hospital of Sichuan UniversityChengdu 610041Sichuan ProvinceChina Center of Hepatology Beijing Ditan HospitalCapital Medical UniversityBeijing 100015China Department of International Medical Beijing Youan HospitalCapital Medical UniversityBeijing 10069China Department of Infectious Diseases Huashan HospitalFudan UniversityShanghai 200040China Department of Infectious Diseases Peking University People's HospitalBeijing 100044China Clinical Center Jiangsu Chia-tai Tianqing Pharmaceutical Co.LtdNanjing 210000Jiangsu ProvinceChina

BACKGROUND Tenofovir disoproxil fumarate(TDF)is a prodrug of a nucleotide *** an antiviral drug,TDF has been proposed in the first-line treatment of chronic hepatitis B(CHB).Qingzhong,a brand name of TDF,commercialized by jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd.,and Viread,another brand name of TDF,commercialized by GlaxoSmithKline,have both been approved by the State Food and Drug Administration,*** To investigate the efficacy and safety of the two TDF agents in the treatment of Chinese CHB *** This trial was registered at *** with the identifier number of NCT02287857.A total of 330 Chinese CHB patients,among which 232 were hepatitis B e antigen(HBeAg)-positive,were included in this 5-year-long,multicenter,double-blinded,double-dummy,randomized-controlled,noninferiority phase III *** participants were initially randomized into two groups:Group A(n=161),in which the participants received 300 mg Qingzhong once a day for 48 wk;and Group B,in which the participants received 300 mg Viread once a day for 48 *** from week 49,all the participants in Groups A and B received 300 mg Qingzhong once a day until the 96th *** this study,the primary endpoint was the decrease in plasma level of hepatitis B virus(HBV)DNA at the 96th week,while the secondary endpoints were suppression of HBV replication,alanine aminotransferase(ALT)normalization,HBeAg loss,and HBeAg seroconversion *** For the participants with HBeAg-positive CHB,the decrease in mean HBV DNA level relative to the baseline value was comparable between Groups A and B(5.77 vs 5.73 log10 IU/mL,P>0.05)at the 96th *** addition,similar percentages of HBeAg-positive participants in the two groups exhibited undetectable levels of HBV DNA,HBeAg loss,and HBeAg seroconversion(71.05%vs 77.97%,31.00%vs 27.27%,and 20.22%vs 15.79%,respectively,in Group A vs Group B;P>0.05).For the participants with HBeAg-negative CHB,the decrease in mean HBV DNA level r

关键词： Chronic hepatitis B Hepatitis B virus infection Chronic Tenofovir disoproxil

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Extracellular vesicles from human urine-derived stem cells prevent osteoporosis by transferring CTHRC1 and OPG

引用

Bone Research 2019年第3期7卷 296-309页

作者： Chun-Yuan Chen Shan-Shan Rao Yi-Juan Tan ming-Jie Luo Xiong-Ke Hu hao Yin Jie Huang Yin Hu Zhong-Wei Luo Zheng-Zhao liu Zhen-Xing Wang Jia Cao Yi-Wei liu Hong-ming li Yang Chen Wei Du jiang-Hua liu Yan zhang Tuan-Hui Chen hao-ming liu Ben wu Tao Yue Yi-Yi Wang Kun Xia Peng-Fei Lei Si-Yuan tang Hui Xie Department of Orthopedics Xiangya Hospital Central South University Changsha Hunan 410008 China Movement System Injury and Repair Research Center Xiangya Hospital Central South University Changsha Hunan 410008 China Xiangya School of Nursing Central South University Changsha Hunan 410013 China Department of Sports Medicine Xiangya Hospital Central South University Changsha Hunan 410008 China Department of Rehabilitation Xiangya Hospital Central South University Changsha Hunan 410008 China Hunan Key Laboratory of Organ Injury Aging and Regenerative Medicine Changsha Hunan 410008 China Hunan Key Laboratory of Bone Joint Degeneration and Injury Changsha Hunan 410008 China National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha Hunan 410008 China

Osteoporosis is a debilitating bone disease affecting millions of people. Here, we used human urine-derived stem cells(USCs),which were noninvasively harvested from unlimited and easily available urine, as a "factory" to obtain extracellular vesicles(USCEVs) and demonstrated that the systemic injection of USC-EVs effectively alleviates bone loss and maintains bone strength in osteoporotic mice by enhancing osteoblastic bone formation and suppressing osteoclastic bone resorption. More importantly, the anti-osteoporotic properties of USC-EVs are not notably disrupted by the age, gender, or health condition(with or without osteoporosis) of the USC donor. Mechanistic studies determined that collagen triple-helix repeat containing 1(CTHRC1) and osteoprotegerin(OPG) proteins are enriched in USC-EVs and required for USC-EV-induced pro-osteogenic and anti-osteoclastic effects. Our results suggest that autologous USC-EVs represent a promising novel therapeutic agent for osteoporosis by promoting osteogenesis and inhibiting osteoclastogenesis by transferring CTHRC1 and OPG.

关键词： stem cells USCs bone loss

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases

引用

Chinese Medical Journal 2017年第20期130卷 2473-2488页

作者： Zou, He-Jian wu, Hu-Sheng Zhou, Jing-guo Zeng, Xue-Jun dai, lie wu, Hua-Xiang zhu, xiao-Xia Mei, Chang-lin hao, Chuan-ming Chen, Nan liu, Bi-Cheng Chen, jiang-Hua Yang, li Nie, Jing Yu, Chen Peng, Ai Yu, Sheng-Qiang li, lin Ge, Jun-Bo Huo, Yong zhang, Shu-Yang Chen, Yun-dai dong, Yu-Gang liang, Chun dai, Yu-Xiang Gao, Xin li, Chang-Gui Zhao, Jia-Jun Chen, Hai-Bing Cheng, Zhi-Feng lin, Huan-dong Guan, Yang-Tai Wang, Kai Luo, Ben-Yan dai, Ruo-lian jiang, Quan Xue, Luan liang, Chao-Chao Chen, ming Fan, Song Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases

INTRODUCTIONThe prevalence of hyperuricenlia （HUA） has increased in China in the recent years in relation to socioeconomic developments and changing lifestyles and diets, with a trend toward onset at younger age. HUA has become the second most common metabolic disease after diabetes mellitus. like gout, HUA is also associated with the occurrence and progression of disorders of the urinary, endocrine, metabolic, cardio-cerebrovascular, and other systems.

关键词： Consensus Gout Hyperuricemia Recommendation Uric Acid

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial

引用

Cancer Communications 2021年第9期41卷 889-903页

作者： Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He minghong Bi Xicheng Wang Jianhua Shi ming Zhou Qian Sun guolei Wang dongji Chen Yongqian Shu lianke liu Zhongliang guo Yong liu Junquan Yang Ke Wang Ke xiao linwu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang tang Yan Wang Puyuan Xing dongqing Lv Wangjun liao Zhiguo Luo Bin Wang xiaohong wu xiaoli zhu Shuhua Han Qisen guo Rongyu liu Zhiwei Lu Jianyong zhang Jian Fang Changlu Hu Yinghua Ji guolong liu Hong Lu Dedong wu Junhong zhang Shuyang zhu Zheng liu Wensheng qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping zhang Wenjuan lian Bo jiang Bo qiu guojun zhang Hua zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang li Shengming liu lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao li Zhao Shumin Wang Can wu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021P.R.China Department of Oncology Yibin Second People’s HospitalYibinSichuan 644000P.R.China Department of Oncology Liuzhou People’s HospitalLiuzhouGuangxi 545006P.R.China Department of Thoracic Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Oncology Department the First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233030P.R.China Department of Oncology the First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouGuangdong 510030P.R.China Department of Internal medicine Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Thoracic Surgery the Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510095P.R.China Department of Internal Medicine-Oncology/Department of thoracic oncology Henan Chest HospitalZhengzhouHenan 450003P.R.China The Second Department of Radiotherapy Wuwei Cancer Hospital of Gansu ProvinceWuweiGansu 730000P.R.China Department of Oncology the People’s Hospital of Jiangsu ProvinceNanjingJiangsu 210000P.R.China Respiratory Medicine Department Shanghai East HospitalShanghai 200120P.R.China The Second Department of Internal Medicine-Oncology Xuzhou Central HospitalXuzhouJiangsu 221009P.R.China Oncology Department Tangshan People’s HospitalTangshanHebei 063001P.R.China Respiratory Medicine Department West China Hospital of Sichuan UniversityChengduSichuan 610041P.R.China Thoracic Surgery the Second Affiliated Hospital of Shantou University Medical CollegeShantouGuangdong 515051P.R.China Internal Medicine-Oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China Department of Oncology Xiangyang Central HospitalXiangyangHubei 441021P.R.China Respiratory Department Lishui Central HospitalLishuiZ

Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or *** primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and *** study was registered in Clinical ***(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)*** of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)*** responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,*** stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY010

关键词： anti-angiogenesis anti-VEGF monoclonal antibody avastin bevacizumab biosimilar nonsmall cell lung cancer LY01008 vascular endothelial growth factor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Searching for ^(76)Ge neutrinoless double beta decay with the CDEX-1B experiment

引用

Chinese Physics C 2024年第10期48卷 11-22页

作者： Bing-Tao zhang Jun-Zheng Wang li-Tao Yang Qian Yue Ke-Jun Kang Yuan-Jing li Hai-Peng An C.Greeshma Jian-Ping Chang Yun-Huan Chen Jian-Ping Cheng Wen-Han dai Zhi Deng Chang-hao Fang Xin-Ping Geng Hui Gong qiu-Ju guo Xu-Yuan guo li He Sheng-ming He Jin-Wei Hu Han-Xiong Huang Tu-Chen Huang Hai-Tao Jia Xi jiang S.Karmakar hao-Bin li Jian-Min li Jin li Qian-Yun li Ren-ming-Jie li Xue-Qian li Yu-Lan li Yi-Fan liang Bin liao Fong-Kay lin Shin-Ted lin Jia-Xuan liu Shu-Kui liu Yan-dong liu Yu liu Yuan-Yuan liu Zhong-Zhi liu hao Ma Yu-Cai Mao Qi-Yuan Nie Jin-Hua Ning Hui Pan Ning-Chun Qi Jie Ren Xi-Chao Ruan Ze She Manoj Kumar Singh Tian-Xi Sun Chang-Jian tang Wei-You tang Yang Tian Guang-Fu Wang li Wang Qing Wang Yu-Feng Wang Yun-Xiang Wang Henry-Tsz-King Wong Shi-Yong wu Yu-Cheng wu hao-Yang Xing Rui Xu Yin Xu Tao Xue Yu-Lu Yan Nan Yi Chun-Xu Yu Hai-Jun Yu Jian-Feng Yue ming Zeng Zhi Zeng Feng-Shou zhang Lei zhang Zhen-Hua zhang Zhen-Yu zhang Kang-Kang Zhao ming-Gang Zhao Ji-Fang Zhou Zu-Ying Zhou Jing-Jun Zhou Key Laboratory of Particle and Radiation Imaging(Ministry of Education)and Department of Engineering Physics Tsinghua UniversityBeijing 100084 Department of Physics Tsinghua UniversityBeijing 100084 Institute of Physics Academia SinicaTaipei 11529 NUCTECH Company Beijing 100084 YaLong River Hydropower Development Company Chengdu 610051 College of Nuclear Science and Technology Beijing Normal UniversityBeijing 100875 College of Physics Sichuan UniversityChengdu 610065 School of Physics Peking UniversityBeijing 100871 Department of Nuclear Physics China Institute of Atomic EnergyBeijing 102413 Sino-French Institute of Nuclear and Technology Sun Yat-sen UniversityZhuhai 519082 School of Physics Nankai UniversityTianjin 300071 Department of Physics Banaras Hindu UniversityVaranasi 221005 Department of Physics Beijing Normal UniversityBeijing 100875

We operated a p-type point contact high purity germanium(PPCGe)detector(CDEX-1B,1.008 kg)in the China Jinping Underground Laboratory(CJPL)for 500.3 days to search for neutrinoless double beta(0νββ)decay of ^(76)Ge.A total of 504.3 kg⋅day effective exposure data was *** anti-coincidence and the multi/single-site event(MSE/SSE)discrimination methods were used to suppress the background in the energy region of interest(ROI,1989–2089 keV for this work)with a factor of 23.A background level of 0.33 counts/(keV⋅kg⋅yr)was *** lower limit on the half life of^(76)Ge 0νββdecay was constrained as T_(1/2)^(0ν)>1.0×10^(23)yr(90%C.L.),corresponding to the upper limits on the effective Majorana neutrino mass:<3.2–7.5 eV.

关键词： neutrinoless double beta decay CDEX point-contact germanium detector ^(76)Ge

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

基于个体化机器学习的原发性免疫性血小板减少症危重出血预测模型:一项全国前瞻性队列研究

引用

Science Bulletin 2023年第18期68卷 2106-2114,M0004页

作者： zhuo-Yu An Ye-Jun wu Yu Hou Heng Mei Wei-Xia Nong Wen-Qian li Hu Zhou Ru Feng Jian-Ping Shen Jun Peng Hai Zhou Yi liu Yong-Ping Song lin-Hua Yang Mei-Yun Fang Jian-Yong li Yun-Feng Cheng Peng liu Ya-Jing Xu Zhao Wang Yi Luo Zhen Cai Hui liu Jing-Wen Wang Juan li Xi zhang Zi-Min Sun xiao-Yu zhu Xin Wang Rong Fu liang Huang Shao-Yuan Wang Tong-Hua Yang li-Ping Su liang-ming Ma Xie-Qun Chen dai-Hong liu Hong-Xia Yao Jia Feng Hong-Yu zhang ming jiang Ze-Ping Zhou Wen-Sheng Wang Xu-liang Shen Yangjin Baima Yue-Ying li Qian-Fei Wang qiu-Sha Huang Hai-Xia Fu xiao-Lu zhu Yun He Qian jiang hao jiang Jin Lu Xiang-Yu Zhao Ying-Jun Chang Tao wu Yao-zhu Pan lin qiu da Gao A-Rong Jin Wei li Su-Jun Gao Lei zhang ming Hou xiao-Jun Huang xiao-Hui zhang on behalf of the National Cooperative ITP Working Group Peking University People’s Hospital Peking University Institute of HematologyBeijing 100044China Collaborative Innovation Center of Hematology Peking UniversityBeijing 100044China Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing 100044China National Clinical Research Center for Hematologic Disease Beijing 100044China Department of Hematology Qilu HospitalCheeloo College of MedicineShandong UniversityJinan 250014China Institute of Hematology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430074China Department of Hematology First Affiliated HospitalSchool of MedicineShihezi UniversityShihezi 832002China Department of Hematology Qinghai Provincial People’s HospitalXining 810007China Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou UniversityHenan Institute of HematologyZhengzhou 450008China Department of Hematology Beijing HospitalBeijing 100044China Department of Hematology Zhejiang Provincial Hospital of Traditional Chinese MedicineHangzhou 310006China Department of Hematology Senior Department of Hematologythe Fifth Medical Center of PLA General HospitalBeijing 100044China Department of Hematology the Second Hospital of Shanxi Medical UniversityTaiyuan 030001China Department of Hematology Affiliated Zhongshan Hospital of Dalian UniversityDalian 116001China Department of Hematology The First Affiliated Hospital with Nanjing Medical University(Jiangsu Province Hospital)Nanjing 210029China Department of Hematology Zhongshan HospitalFudan UniversityShanghai 200032China Department of Hematology Xiangya HospitalCentral South UniversityChangsha 410008China Department of Hematology Beijing Friendship HospitalCapital Medical UniversityBeijing 100044China Institute of Hematology the First Affiliated HospitalZhejiang UniversityHangzhou 310058China Department of Hematology Beijing Tongren HospitalBeijing 100005China Department of Hematology The First Affiliated HospitalSun Yat-sen UniversityGuang

原发性免疫性血小板减少症(ITP)中少见但至关重要的危重出血事件,给患者的预后、生活质量和治疗决策带来严重影响。尽管有一些研究探讨了ITP中与危重出血相关的风险因素,但目前尚缺乏大样本数据、大规模多中心研究结果以及针对ITP患者... 详细信息

原发性免疫性血小板减少症(ITP)中少见但至关重要的危重出血事件,给患者的预后、生活质量和治疗决策带来严重影响。尽管有一些研究探讨了ITP中与危重出血相关的风险因素,但目前尚缺乏大样本数据、大规模多中心研究结果以及针对ITP患者致命出血事件的预测模型。本研究首次采用国际血栓与止血学会新提出的ITP致命出血标准,利用大样本数据开发了首个基于机器学习的在线应用,用于预测ITP患者的致命出血.研究中,我们使用中国各地大型多中心数据进行开发,并对全国39家医疗中心进行为期一年的外部测试,得到了较好的训练、验证和测试数据集预测能力该基于新算法的便捷网络工具能够快速识别ITP患者的出血风险,辅助临床决策,有望未来降低不良事件的发生。

关键词： Critical bleeding Severe bleeding Immune thrombocytopenia Machine learning Prediction model

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A joint call for actions to advance taxonomy in China

引用

Zoological Systematics 2022年第3期47卷 188-197页

作者： Chaodong zhu Arong Luo ming Bai Michael COrr Zhonge Hou Siqin Ge Jun Chen Yibo Hu Xuming Zhou Gexia Qiao Hongzhi Kong limin Lu xiaohua Jin Lei Cai Xinli Wei Ruilin Zhao Wei Miao Qingfeng Wang Zhongli Sha Qiang lin Meng Qu Jianping jiang Jiatang li Jing Che Xuelong jiang xiaoyong Chen lianming Gao Zongxin Ren Chunlei Xiang Shixiao Luo donghui wu dong liu Yanqiong Peng Tao Su Chenyang Cai Tianqi zhu Wanzhi Cai Xingyue liu Hu li Huaijun Xue Zhen Ye Xuexin Chen Pu tang Shujun Wei Hong Pang Qiang Xie Feng zhang Feng zhang Xianjin Peng Aibing zhang Taiping Gao Changfa Zhou Chen Shao libin Ma Zhaoming Wei Yunxia Luan Ziwei Yin wu dai Cong Wei xiaolei Huang Jingxian liu Xiangsheng Chen Tianci Yi Zhisheng zhang zhulidezi Aishan Qin li Hongying Hu CAS Key Laboratory of Zoological Systematics and Evolution Institute of ZoologyChinese Academy of SciencesBeijing 100101China CAS Key Laboratory of Animal Ecology and Conservation Biology Institute of ZoologyChinese Academy of SciencesBeijing 100101China State Key Laboratory of Systematic and Evolutionary Botany Institute of BotanyChinese Academy of SciencesBeijing 100093China State Key Laboratory of Mycology(SKLM) Institute of MicrobiologyChinese Academy of SciencesBeijing 100101China CAS Key Laboratory of Aquatic Biodiversity and Conservation Institute of HydrobiologyChinese Academy of SciencesWuhan 430072China wuhan Botanical Garden Chinese Academy of SciencesWuhan 430074China Department of Marine Organism Taxonomy&Phylogeny Institute of OceanologyChinese Academy of SciencesQingdao 266071China CAS Key Laboratory of Tropical Marine Bio-resources and Ecology South China Sea Institute of OceanologyChinese Academy of SciencesGuangzhou 510301China CAS Key Laboratory of Mountain Ecological Restoration and Bioresource Utilization&Ecological Restoration and Biodiversity Conservation Key Laboratory of Sichuan Province Chengdu Institute of BiologyChinese Academy of SciencesChengdu 610041China State Key Laboratory of Genetic Resources and Evolution&Yunnan Key Laboratory of Biodiversity and Ecological Security of Gaoligong Mountain Kunming Institute of ZoologyChinese Academy of SciencesKunming 650221China CAS Key Laboratory for Plant Diversity and Biogeography of East Asia Kunming Institute of BotanyChinese Academy of SciencesKunming 650201China CAS Key Laboratory of Plant Resource Conservation and Sustainable Utilization South China Botanical GardenChinese Academy of SciencesGuangzhou 510650China CAS Key Laboratory of Wetland Ecology and Environment Northeast Institute of Geography and AgroecologyChinese Academy of SciencesChangchun 130102China CAS Key Laboratory of Tropical Forest Ecology Xishuangbanna Tropical Botanical GardenChinese Academy of SciencesMenglunMenglaYunnan 66630

Taxonomy plays an important role in understanding the origin, evolution, and ecological functionality of biodiversity. There are large number of unknown species yet to be described by taxonomists, which together with their ecosystem services cannot be effectively protected prior to description. Despite this, taxonomy has been increasingly underrated insufficient funds and permanent positions to retain young talents. Further, the impact factordriven evaluation systems in China exacerbate this downward trend, so alternative evaluation metrics are urgently necessary. When the current generation of outstanding taxonomists retires,there will be too few remaining taxonomists left to train the next generation. In light of these challenges, all co-authors worked together on this paper to analyze the current situation of taxonomy and put out a joint call for immediate actions to advance taxonomy in China.

关键词： Endangered taxonomists morphology-based taxonomy integrative taxonomy capacity building systematics

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

引文网络加速转化医学T1-T2-T3阶段的转化进程

引用

中华临床营养杂志 2013年第2期21卷 98-102页

作者：杜建唐小利张燕舞张玢蒋朱明中国医学科学院北京协和医学院医学信息研究所信息服务部 100020 中国医学科学院北京协和医学院北京协和医院基本外科 100730

Dougherty和Conway的转化医学“3T”模式体现了T1（基础研究到临床有效性研究）、他（临床有效性研究到临床疗效研究）、仍（临床疗效研究到与经济有关的研究和改进医疗服务质量）阶段的相互转化过程，可作为测量转化研究的基础框架。... 详细信息

Dougherty和Conway的转化医学“3T”模式体现了T1（基础研究到临床有效性研究）、他（临床有效性研究到临床疗效研究）、仍（临床疗效研究到与经济有关的研究和改进医疗服务质量）阶段的相互转化过程，可作为测量转化研究的基础框架。文献之间的引用与被引用关系形成的“引文网络（citationnetwork）”揭示出具体领域的转化地带、转化路径和转化时滞，可使科研人员把握该领域转化研究的关键内容与路线图，促进研究从上游吸收和向下游转化，最终加速转化医学进程。利用文献的引文网络可对不同研究阶段之间的转化关系进行测量。本文基于文献“引文网络”分析方法，介绍“3T”模式下的转化研究测量模型。

关键词： 3T模式转化研究引文网络

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database

引用

Asian Journal of Urology 2015年第2期2卷 63-69页

作者： Kaiwen li Tianxin lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong li Lulin Ma guoliang Wang Chaozhao liang haoqiang Shi ming li Mao tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang li Zhiwen Chen xiaozhou Zhou Fengshuo Jin Xudong liu Jinxin Wei Lei Shi Xin Gou Weiyang He liqun Zhou lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi wu dongwen Wang Hailong hao Benkang Shi Yaofeng zhu Qiang Wei Ping Han Changli wu dawei Tian zhangqun Ye Zheng liu Zhiping Wang Junqiang Tian lin Qi Minfeng Chen Wei li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei zhu Jinchun Xing zhun wu dong Wei Xin Chen Yanqun Na Hongfeng guo Chunxi Wang Zhihua Lu Chuize Kong Yang liu Jin Yang Jianyun Hu Xin Gao Jielin li Changjun Yin Pu li Shan Chen Zhen Du Jiongming li Yongji Yan Xu zhang Shuang Huang Fangjian Zhou Zhiling zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong li Jin Wen Jian Huang Department of Urology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouChina Chinese Bladder Cancer Consortium Department of Urology Renji HospitalShanghai Jiaotong University School of MedicineShanghaiChina Department of Urology Fujian Medical University Union HospitalFuzhouChina Department of Urology General Hospital of Ningxia Medical UniversityYinchuanChina Department of Urology Peking University Third HospitalBeijingChina Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefeiChina Department of Urology The Xinjiang Uygur Autonomous Region People’s HospitalUygurChina Department of Urology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina Department of Urology The First Affiliated Hospital of Guangxi Medical UniversityNanningChina Department of Urology Southwest HospitalThird Military Medical UniversityChongqingChina Department of Urology Daping HospitalThird Military Medical UniversityChongqingChina Department of Urology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina Department of Urology The First Affiliated Hospital of Chongqing Medical UniversityChongqingChina Department of Urology Peking University First HospitalBeijingChina Department of Urology The First Affiliated Hospital of Zhejiang UniversityHangzhouChina Department of Urology China Japan Friendship Hospital of Jilin UniversityChangchunChina Department of Urology Beijing Friendship HospitalCapital Medical UniversityBeijingChina Department of Urology Wuhan General Hospital of Guangzhou MilitaryWuhanChina Department of Urology The First Affiliated Hospital of Shanxi UniversityTaiyuanChina Department of Urology Qilu Hospital of Shandong UniversityJinanChina Department of Urology West China HospitalSichuan UniversityChengduChina Department of Urology The Second Affiliated Hospital of Tianjin Medical UniversityTianjinChina Department of Urology Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Objective:To investigate current status of diagnosis and treatment of bladder cancer in ***:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were *** of diagnosis,treatment and pathology were ***:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,***-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,*** transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,*** MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,*** most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant ***:Disease characteristics are similar to international reports,while differences of diagnosis and treatment *** study can provide evidences for revisions of the guideline on bladder cancer in China.

关键词： Bladder cancer Diagnosis Treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Consensus statement on layout and delivery of automatic external defibrillator in China

引用

Journal of Hainan Medical University 2020年第15期26卷 18-23页

作者： Yu Cao Song Chen Yan-Fen Chai xiao-Hui Chen Yu-guo Chen Shao-Wen Cheng Wen-Wei Cheng Bang-Han Ding Yang Deng Jie Fu Bang-jiang Fang Mai-Ying Fan li Gui Ping Gong Wei guo Shu-Bin guo liang Huang Ji-Yuan Han Zhong Ji Xian-Fei Ji Xin-Cai Ji Hong-Xu Jin Xin-Jun jiang Wang-Xiang jiang Jia-liang liu xiao-Ran liu Zhi liu Chuan-zhu Lv Feng Lu Tan-Shi li Xin li Yong li Shang-Lun li Shuang-ming li xiao-Gang li Bao-Jun li Pei-wu li Chun-Sheng li Zhi-Jun li Chang-Luo li Xiang-Min li Yin-Ping li Zong-Jun Lu Zu-Xun Lu Zhong-qiu Lu Zhi-Qian Luo xiao-Xing liao Jian-Bo Lei Tao Ma Yu Ma Yue-Feng Ma Qing-Bian Ma lin-hao Ma Jun-Qi Ma Shi-Nan Nie Jie-Miao Ou-Yang Peng Peng Qiao Pei Shu-ming Pan guo-Zhong Qing li-Jie Qin wu-Ying Qiao Fei Shao Wei Song Xing-Yue Song Zhen-Ju Song Rong-Ju Sun De-Ya Shang Du-Juan Sha Gui-Lan Tao guo-Gang Tian Ying-Ping Tian Jian-Guang Tian Chao-Yang Tong Zi-Ren tang Meng-Xiong tang guo-Ping wu Zhi Wan Tao Wang Xin Wang Peng Wang Zhong Wang Tong Wang Ri-Xing Wang Yi-Xin Wang xiao-dan Wang ling wu Wei Wei Hua Xiang Feng Xu Jun Xu Jie Xu Miao-Rong Xie Shuo-Gui Xu Tie Xu Feng Yu Wen Yi li-Shan Yang Shi-Jiao Yan Jin-Jian Yao Shou-Chun Yan Xue-Zhong Yu Xian-Zhi Ye Xian-liang Yan Fu-Bing Zhou Rong-Bin Zhou ming Zhou Qiang Zhou Jin Zhou Ping Zhou Chang-Ju zhu Hua-dong zhu Ji-Hong zhu Hong zhang Mao zhang Hua zhang Na zhang guo-Qiang zhang guo-Xiu zhang Jin-Song zhang Wen-wu zhang Wen-Zhong zhang Jian-Feng zhang Yi-Min zhu Jun Zeng Yuan Zheng Zhi-Jie Zheng Shen Zhao Yan Zhao Min Zhao Bin Zhao xiao-dong Zhao xiao-Jing Zhao Hong-Ke Zeng Sheng-Qiang Zou The Chinese Society of Emergency Medicine Research Unit of Island Emergency Medicine Chinese Academy of Medical SciencesHainan Medical University Key Laboratory of Emergency and Trauma of Ministry of Education Hainan Medical UniversityHaikouHainanChina Emergency and Trauma College Hainan Medical UniversityHaikouHainanChina Department of Emergency Hainan Clinical Research Center for Acute and Critical DiseasesThe Second Affiliated Hospital of Hainan Medical UniversityHaikouHainanChina Key Laboratory of Hainan Trauma and Disaster Rescue Key Laboratory of Trauma of Hainan Medical University

*** Sudden cardiac death(SCD)refers to sudden death due to a variety of cardiac *** is manifested as a sudden loss of consciousness,cardiac arrest,and respiratory arrest and generally shows early symptoms that are atypical and not easily detected[1].According to a recent study,nearly 544000 patients suffer from SCD every year in China[2].

关键词： cardiac death respiratory

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：